Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells.
- Author:
Ji Sung KIM
1
;
Yong Guk KIM
;
Eun Jae PARK
;
Boyeong KIM
;
Hong Kyung LEE
;
Jin Tae HONG
;
Youngsoo KIM
;
Sang Bae HAN
Author Information
- Publication Type:Review
- Keywords: Cytokine-induced killer cells; Colorectal cancer; Cell-based immunotherapy
- MeSH: Cell- and Tissue-Based Therapy; Colorectal Neoplasms*; Cytokine-Induced Killer Cells*; Dendritic Cells; Drug Therapy, Combination; Humans; Immunotherapy*; Incidence; Lymph Nodes; Mortality; Prognosis; Quality of Life; Survival Rate; Vaccines
- From:Immune Network 2016;16(2):99-108
- CountryRepublic of Korea
- Language:English
- Abstract: Colorectal cancer is the third leading cancer worldwide. Although incidence and mortality of colorectal cancer are gradually decreasing in the US, patients with metastatic colorectal cancer have poor prognosis with an estimated 5-year survival rate of less than 10%. Over the past decade, advances in combination chemotherapy regimens for colorectal cancer have led to significant improvement in progression-free and overall survival. However, patients with metastatic disease gain little clinical benefit from conventional therapy, which is associated with grade 3~4 toxicity with negative effects on quality of life. In previous clinical studies, cell-based immunotherapy using dendritic cell vaccines and sentinel lymph node T cell therapy showed promising therapeutic results for metastatic colorectal cancer. In our preclinical and previous clinical studies, cytokine-induced killer (CIK) cells treatment for colorectal cancer showed favorable responses without toxicities. Here, we review current treatment options for colorectal cancer and summarize available clinical studies utilizing cell-based immunotherapy. Based on these studies, we recommend the use CIK cell therapy as a promising therapeutic strategy for patients with metastatic colorectal cancer.
